We bring you the latest news from the healthcare about the health care in the United Kingdom.

dinsdag 30 oktober 2018

Nature Reviews Drug Discovery contents  November 2018 Volume 17 Number 11 pp 769-844

Nature Reviews Drug Discovery


Advertisement
Expand Your Drug Discovery Pipeline — Target Cell Metabolism with Agilent Seahorse XF Analyzers

Discover novel drug targets for oncology, neurodegeneration, diabetes & cardiovascular disease. Begin your search for cell metabolism targets arranged by disease indication & build your pipeline now! 

Download the guide book to advance your target identification studies.
TABLE OF CONTENTS

November 2018 Volume 17, Issue 11

Comment
News and Analysis
Research Highlights
Reviews
Corrigenda

Advertisement
 
Do you have a career question?
The Naturejobs podcast features one-on-one Q&As, panel discussions and other exclusive content to help scientists with their careers. Hosted on the Naturejobs blog, the podcast is also available on iTunes and Soundcloud. 

Listen today! 


Advertisement

BIOPHARMA DEALMAKERS
BIOPHARMA DEALMAKERSCompany Profiles and Partnering Opportunities


 
Advertisement
Travel grants for early career researchers
 
Communications journals (Biology, Chemistry and Physics) are pleased to introduce their first travel grants for early career researchers. The programme aims to help promising researchers travel to an international scientific meeting of their choice. 

The application period is open until 5th November. 
 

Comment

Impact of the Innovative Medicines Initiative on vaccine development   
Philippe Denoel, Patricia Londoño-Hayes, Magda Chlebus & Magdalena Rodriguez de Azero
pp769 - 770 | doi:10.1038/nrd.2018.72
Since its launch a decade ago, the European Innovative Medicines Initiative (IMI), a leading public–private partnership in life sciences, has catalysed scientific breakthroughs and the development of strategies to address complex challenges in various biomedical fields. Here, we discuss the progress of IMI projects related to vaccine research and development.
Full Text | PDF



News and Analysis

Cancer stem cell pipeline flounders   
Ken Garber
pp771 - 773 | doi:10.1038/nrd.2018.157
With clinical failures mounting and companies disinvesting, researchers are revising the cancer stem cell model.
Full Text | PDF



'Party drug' turned antidepressant approaches approval   
Sara Reardon
pp773 - 775 | doi:10.1038/nrd.2018.187
Johnson & Johnson has submitted its esketamine for regulatory approval, but researchers still don't understand how the fast-acting antidepressant lifts moods.
Full Text | PDF



News in Brief
Re-assessing the rule of 5, two decades on   
Asher Mullard
p777 | doi:10.1038/nrd.2018.197
Full Text | PDF



How much do phase III trials cost?   
Asher Mullard
p777 | doi:10.1038/nrd.2018.198
Full Text | PDF



FDA approves first drug under new antibacterial and antifungal drug programme   
Asher Mullard
p777 | doi:10.1038/nrd.2018.199
Full Text | PDF



Biobusiness Briefs
Patent watch: Selective GABAA receptor modulators: intellectual property landscape   
Cecilia Martin & Drew Lowery
p778 | doi:10.1038/nrd.2018.179
Full Text | PDF



Regulatory watch: FDA new drug approvals in Q3 2018   
Lisa Urquhart
p779 | doi:10.1038/nrd.2018.194
Full Text | PDF



An Audience With
Martin VanTrieste   
pp780 - 781 | doi:10.1038/nrd.2018.193
Martin VanTrieste, CEO of Civica Rx and former chief quality officer for Amgen, discusses how his hospital-backed non-profit generic drug company plans to bring stability to the generic drug market.
Full Text | PDF



From the analyst's couch
Trends in the global immuno-oncology landscape   
Jun Tang, Laura Pearce, Jill O'Donnell-Tormey & Vanessa M. Hubbard-Lucey
pp783 - 784 | doi:10.1038/nrd.2018.167
This report analyses the dramatic progress in the global immuno-oncology landscape from September 2017 to September 2018.
Full Text | PDF
Collection: Cancer at Nature Research


Advertisement
Focal Point on Kobe

A seismic shift - How Kobe rebuilt itself after a devastating earthquake and turned into a biotechnology hub
 

Research Highlights

Antibacterial agents: New antibiotic hits Gram-negative bacteria
Katie Kingwell
p785 | doi:10.1038/nrd.2018.182
PDF



Antibacterial agents: Gallium fights infection in phase I trial
Sarah Crunkhorn
p786 | doi:10.1038/nrd.2018.186
PDF



Infectious diseases: Smart combinations to prevent HIV rebound
M. Teresa Villanueva
p787 | doi:10.1038/nrd.2018.195
PDF



Cancer: Epilepsy caused by BRAF-mutated paediatric brain tumours gets a REST
Megan Cully
p788 | doi:10.1038/nrd.2018.185
PDF



In Brief
Antibacterials: Curing infection with antibacterial drones
Sarah Crunkhorn
p788 | doi:10.1038/nrd.2018.188
PDF



Rare diseases: Repurposing ciclopirox
Sarah Crunkhorn
p788 | doi:10.1038/nrd.2018.189
PDF



Mitochondrial disease: Eliminating mutant mitochondrial DNA
Sarah Crunkhorn
p788 | doi:10.1038/nrd.2018.190
PDF



Drug Discovery
EVENT
Innovation and Biomarkers in Cancer Drug Development (IBCD)
29.11.18
Brussels, Belgium
More science events from

Reviews

Targeting G protein-coupled receptor signalling by blocking G proteins   
Adrian P. Campbell & Alan V. Smrcka
pp789 - 803 | doi:10.1038/nrd.2018.135
Identifying ligands of G protein-coupled receptors (GPCRs) that elicit biased downstream signalling is an established strategy for separating the desired and unwanted effects of these receptors. Campbell and Smrcka describe how inhibiting the downstream G proteins themselves could also be used to bias GPCR signalling, as well as block pathways shared by multiple GPCRs involved in complex diseases, and discuss how the currently available G protein ligands could be optimized to generate therapeutic leads.
Full Text | PDF



Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs   
Delphine Charvin, Rossella Medori, Robert A. Hauser & Olivier Rascol
pp804 - 822 | doi:10.1038/nrd.2018.136
Existing dopaminergic-based therapies for Parkinson disease (PD) are limited by side effects and lack of long-term efficacy. Here, Charvin et al. discuss the challenges facing the development of novel treatments for PD, assess emerging disease-modifying non-dopaminergic therapeutic strategies and highlight novel therapies aimed at managing symptoms of the disease.
Full Text | PDF



Regulatory T cells in the treatment of disease   
Amir Sharabi, Maria G. Tsokos, Ying Ding, Thomas R. Malek, David Klatzmann et al.
pp823 - 844 | doi:10.1038/nrd.2018.148
Regulatory T cells are important in controlling immune reactions and thus are implicated in autoimmune diseases, transplantation and cancer. In this Review, Tsokos and colleagues discuss how these cells can be harnessed or manipulated for therapeutic use and describe the progress that has been made as well as impending challenges.
Full Text | PDF



Corrigendum

Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs   
Delphine Charvin, Rossella Medori, Robert A. Hauser & Olivier Rascol
p844 | doi:10.1038/nrd.2018.184
Full Text | PDF



Advertisement
Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours.

Click here to sign up.
 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

This email has been sent to dezorgsector.uk@gmail.com.

If you no longer wish to receive the email alerts from Nature Reviews Drug Discovery click here to unsubscribe .
If you wish to discontinue all email services from Nature Research please click here to unsubscribe .

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Macmillan Publishers Limited is a company incorporated in England & Wales under company number 785998 & whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. Nature Research | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Nature is part of Springer Nature. © 2018 Springer Nature Limited. All rights reserved.

Springer Nature